Drugs / DIOXYDINE
DIOXYDINE
also known as
Hydroxymethylquinoxalindioxyde · Chinoxalindimethanol dioxide · Dioxidin · Dioxidine · Metrosept
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05505097 | May → Dec 2022 | infectious disease | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05561816 | Jul → Nov 2022 | pyoderma | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07393711 | Mar → Jun 2026 overdue | nephrolithiasis, urinary tract infection | West Kazakhstan Marat Ospanov Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIOXYDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314960 ↗ |
| Known as | Chinoxalindimethanol dioxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314960 ↗ |
| Known as | Dioxidin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314960 ↗ |
| Known as | Dioxidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07393711 ↗ |
| Known as | Hydroxymethylquinoxalindioxyde | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561816 ↗ |
| Known as | Metrosept | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314960 ↗ |
| Modality | Small molecule | — CHEMBL5314960 ↗ |
| Route | Topical | “solution for topical and external use” NCT05505097 ↗ |